Tag Archives: Carl Byrnes

Northland Securities Remains a Buy on PolarityTE (PTE)

Northland Securities analyst Carl Byrnes maintained a Buy rating on PolarityTE (PTE – Research Report) today and set a price target of $20.00. The company’s shares closed last Monday at $2.97, close to its 52-week low of $2.10. According to

Analysts Offer Insights on Healthcare Companies: Zogenix (NASDAQ: ZGNX) and Aslan Pharmaceuticals (NASDAQ: ASLN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zogenix (ZGNX – Research Report) and Aslan Pharmaceuticals (ASLN – Research Report) with bullish sentiments. Zogenix (ZGNX) In a report released today,

Aridis Pharmaceuticals (ARDS) Receives a Buy from Northland Securities

Northland Securities analyst Carl Byrnes maintained a Buy rating on Aridis Pharmaceuticals (ARDS – Research Report) today and set a price target of $22.00. The company’s shares closed last Monday at $5.00, close to its 52-week low of $4.85. According

Nabriva (NBRV) Receives a Buy from Northland Securities

Northland Securities analyst Carl Byrnes maintained a Buy rating on Nabriva (NBRV – Research Report) today and set a price target of $12.50. The company’s shares closed last Monday at $1.98. According to TipRanks.com, Byrnes has 0 stars on 0-5

Heron Therapeutics (HRTX) Gets a Buy Rating from Northland Securities

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Heron Therapeutics (HRTX – Research Report), with a price target of $47.00. The company’s shares closed last Monday at $20.74. According to TipRanks.com, Byrnes ‘

Northland Securities Maintains a Buy Rating on Adamas Pharmaceuticals (ADMS)

Northland Securities analyst Carl Byrnes maintained a Buy rating on Adamas Pharmaceuticals (ADMS – Research Report) today and set a price target of $15.00. The company’s shares closed last Monday at $4.70, close to its 52-week low of $3.35. According